[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363025-105":59,"doc-detail-363025-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","a-differentiated-thyroid-carcinoma-specific-graded-prognostic-assessment-for-brain-metastases-derivation-in-a-10306-patient-cohort-and-external-validation","A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases - derivation in a 10,306-patient cohort and external validation","","Background: Brain metastases from differentiated thyroid carcinoma (DTC) are uncommon yet carry markedly worse outcomes than extracranial metastatic disease. Existing prognostic tools for brain metastases are not designed for DTC, constraining accurate risk stratification and treatment guidance. Methods: A retrospective single-center cohort of 10,306 DTC patients (2011–2025) was analyzed; multivariable Cox regression identified independent overall-survival factors, forming a DTC-specific graded prognostic assessment (DTC-GPA) with Harrell’s C-index, followed by external validation using case-series data. Results: Among 10,306 patients, 146 (1.4%) had brain metastases. External validation in 83 patients supported clinical applicability. Conclusions: DTC-GPA is the first validated, disease-specific prognostic tool for this rare, heterogeneous population.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-differentiated-thyroid-carcinoma-specific-graded-prognostic-assessment-for-brain-metastases-derivation-in-a-10306-patient-cohort-and-external-validation/363025/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-differentiated-thyroid-carcinoma-specific-graded-prognostic-assessment-for-brain-metastases-derivation-in-a-10306-patient-cohort-and-external-validation/363025.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"Why is a DTC-specific prognostic model needed for brain metastases?","Question",{"text":113,"@type":114},"Brain metastases from differentiated thyroid carcinoma are rare but have substantially poorer prognosis, and existing brain-metastasis scores are derived from other cancers rather than DTC biology. This limits risk stratification and treatment guidance for DTC patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the DTC-GPA model developed?",{"text":118,"@type":114},"A retrospective cohort of 10,306 DTC patients treated from 2011 to 2025 was analyzed. Multivariable Cox regression identified independent factors for overall survival after brain metastases diagnosis, which were then used to build the DTC-GPA score.",{"name":120,"@type":111,"acceptedAnswer":121},"What factors define the DTC-GPA score and how does it relate to survival?",{"text":122,"@type":114},"The DTC-GPA uses three independent factors: ECOG performance status ≥ 2, presence of multiple brain metastases, and an interval ≥ 3 years between primary DTC and brain metastases diagnosis. Scores (0–3) correspond to median overall survival of 7.7 months (0), 22.9 months (1), and 61.3 months (2–3).",{"name":124,"@type":111,"acceptedAnswer":125},"How was external validation performed and what did it show?",{"text":126,"@type":114},"External validation used individual-level data from published case series identified via systematic review. The model demonstrated similar discrimination (C-index 0.68 in the external validation cohort), supporting clinical applicability.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},363025,1790332899,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":41,"preview_page_count":19,"preview_urls":150},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Journal of Neuro-Oncology (2026) 177:105  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1060-026-05507-5  \nRESEARCH  \nA differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation  \nHamza A. Salim1,4 · Sarimar Agosto2 · Heba Al Qudah1 · Kim Learned1 · Mark Zafereo3 · Jennifer Wang3 · Mimi I. Hu5 · Ahmed Msherghi1 · Naifa Busaidy5 · F. Eymen Ucisik1 · Sarah Hamidi5 · Hussein Tawbi6 · RamiW. Eldaya1 · Jing Li7 · Max Wintermark1,4 · Maria E. Cabanillas5  \nReceived: 3 November 2025 / Accepted: 3 March 2026 / Published online: 14 April 2026 © The Author(s) 2026  \nAbstract  \nBackground Brain metastases from differentiated thyroid carcinoma (DTC) are rare but associated with significantly worse prognosis compared to extracranial metastatic sites. Existing prognostic models for brain metastases are not tailored to DTC, limiting risk stratification and therapeutic guidance in this population.  \nMethods We conducted a retrospective cohort study of 10,306 patients with DTC treated at a single tertiary cancer center from 2011 to 2025. Patients with radiologically or pathologically confirmed brain metastases were included. Multivariable Cox regression was used to identify independent prognostic factors for overall survival (OS), defined from the time of Brain metastases diagnosis. Based on these factors, we developed the Differentiated Thyroid Cancer Graded Prognostic Assessment (DTC-GPA) and evaluated its discriminatory performance using Harrell’s C-index. External validation was performed using individual-level data from published case series identified via systematic review.  \nResults Of 10,306 patients with DTC, 146 (1.4%) were found to have brain metastases. The median OS after Brain metastases diagnosis was 20.4 months. ECOG performance status ≥ 2 (HR, 2.67; 95% CI, 1.65–4.30; p\u003C 0.001), presence ofmultiple brain metastases (HR, 2.30; 95% CI, 1.39–3.82; p = 0.002), and interval ≥ 3years between primary DTC and Brain metastases diagnosis (HR, 1.84; 95% CI, 1.03–3.27; p = 0.03) were independently associated with worse OS. These three factors formed the DTC-GPA, assigning one point for each favorable variable (range: 0–3) . Median OS by score group was 7.7 months (score 0), 22.9 months (score 1), and 61.3 months (score 2–3) . The C-index was 0.70 in the derivation cohort and 0.68 in the external validation cohort of 83 patients.  \nConclusions The DTC-GPA is the first validated, disease-specific prognostic tool for patients with brain metastases from DTC. This simple, three-point score offers clinically meaningful risk stratification to guide treatment decisions and prognosis estimation in a rare and heterogeneous patient population.  \nKey points  \n• First validated prognostic score for thyroid cancer brain metastases  \n• DTC-GPA stratifies survival with simple 3-point system  \n• External validation confirms clinical applicability  \nImportance of the Study  \nBrain metastases from differentiated thyroid carcinoma (DTC) are rare and lack validated prognostic tools. Existing scores are derived from other cancers and do not reflect the unique biology of DTC. Using the largest single-institution cohort to date and external validation, we developed the Differentiated Thyroid Carcinoma Graded Prognostic Assessment (DTCGPA), a simple three-factor model. This tool provides disease-specific risk stratification, enabling more accurate survival estimation and informing treatment strategies in a heterogeneous population. The DTC-GPA addresses a longstanding gap in neuro-oncology and will facilitate more consistent patient counseling, clinical trial design, and comparative effectiveness research in this rare group of patients.  \nKeywords Differentiated thyroid carcinoma · Brain metastases · Prognostic score · DTC-GPA · Overall survival · Risk stratification  \nExtended author information available on the last page of the article  \nIntroduction  \nD","cbCaiuppunxO65iA","https://ap.wps.com/l/cbCaiuppunxO65iA","pdf",3070857,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Key points\n# Importance of the Study\n# Introduction","[{\"question\":\"Why is a DTC-specific prognostic model needed for brain metastases?\",\"answer\":\"Brain metastases from differentiated thyroid carcinoma are rare but have substantially poorer prognosis, and existing brain-metastasis scores are derived from other cancers rather than DTC biology. This limits risk stratification and treatment guidance for DTC patients.\"},{\"question\":\"How was the DTC-GPA model developed?\",\"answer\":\"A retrospective cohort of 10,306 DTC patients treated from 2011 to 2025 was analyzed. Multivariable Cox regression identified independent factors for overall survival after brain metastases diagnosis, which were then used to build the DTC-GPA score.\"},{\"question\":\"What factors define the DTC-GPA score and how does it relate to survival?\",\"answer\":\"The DTC-GPA uses three independent factors: ECOG performance status ≥ 2, presence of multiple brain metastases, and an interval ≥ 3 years between primary DTC and brain metastases diagnosis. Scores (0–3) correspond to median overall survival of 7.7 months (0), 22.9 months (1), and 61.3 months (2–3).\"},{\"question\":\"How was external validation performed and what did it show?\",\"answer\":\"External validation used individual-level data from published case series identified via systematic review. The model demonstrated similar discrimination (C-index 0.68 in the external validation cohort), supporting clinical applicability.\"}]","A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases - derivation in a 10,306-patient cohort and external validation | PDF",1790149682,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0471a6a652eeea5ce299dc3143832b1.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe243996c959bffc16b8a68f1895b0da.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/482fc39ccdfa427a2890fc918a08da03.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b9f89e8c9576a5540da989612fac3df.webp",980,1301]